top of page
Cancer Research & Precision Drug Delivery
March 2025 | IVPMED
Cancer Research & Precision Drug Delivery
At IVPMED, we are pushing the boundaries of cancer treatment by focusing on what matters most: precision, absorption, and targeted delivery. Our technology enables therapeutic agents to reach cancer cells with higher accuracy and less systemic exposure — offering better outcomes, especially in dose-sensitive conditions like breast cancer.

Nano Suspension for Targeted Drug Distribution
Our cancer-focused formulations are built on nano suspension technology, which breaks active pharmaceutical ingredients into ultra-fine particles for:
-
Improved solubility and absorption.
-
Enhanced bioavailability at the tumor site.
-
Reduced side effects compared to conventional systemic delivery.
-
There is appetite for non-IV dosing of medication as a patient-centered approach.
-
Patients finding this very attractive.
This system is optimized for administration through the Nebulizer, allowing clinicians to control dose, track delivery, and monitor patient adherence remotely.
Real-Time Tracking and AI Dosing Support
Cancer patients often require strict dosing schedules and treatment personalization. Our platform integrates:
-
Smart scheduling algorithms for time-sensitive dosing.
-
AI-powered dashboards to adapt doses per patient response.
-
Connected wearable and nebulizer feedback loops.
-
Remote monitoring for clinical oversight and adherence.
The goal: Deliver drugs when they’re most effective, and monitor the body’s response continuously.
Use Cases & Clinical Integration
-
Breast cancer nanoformulation trials.
-
Hormone-sensitive cancer therapies.
-
Pre/post-op recovery treatment delivery.
-
Personalized chemotherapy support systems
Supporting Research Materials
Design and Development of Breast Cancer Research Using Nano Suspension Effective Dosing and Tracking with the Slyder Device
These documents outline preclinical and pilot-stage results, delivery protocols, and data-tracking architecture.
bottom of page


